Investor Relations

Our mission is to prevent and treat severe GI diseases by restoring and protecting the GI mucosal-immune system and advancing our therapeutic pipeline and GI discovery platform.

Latest Investor Updates

32 Biosciences one-pager

Quarter 4, 2025

Quarter 3, 2025

Quarter 2, 2025

Quarter 1, 2025

Pipeline - Learn more

Press Releases

January 8, 2026

32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics

Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
December 31, 2025

32 Biosciences Set to Attend the 2026 JPM Healthcare Conference

Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
December 31, 2025

32 Biosciences Joins Featured Startups in the Midwest Biotech Startup Showcase

Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
June 10, 2025

32 Biosciences Surpasses Financing Target, Accelerates Toward Series A and FDA Milestones 

Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
October 19, 2024

Microbiota-dependent Early-life Programming of Gastrointestinal Motility

September 27, 2024

UChicago Microbiome Startups Come Together Under New Company to Amplify Results

Our Solutions

First in class evidence-based solutions to treat and prevent human disease by diagnosing and treating dysbiosis.

Image of a gut, with wordse 'Focus on the Gut Microbiome to Prevent and Treat Disease' around it.

Generating data to develop microbiome-based interventions.